पित्तवाहिनी कर्करोग (Bile duct cancer)
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
कुठे जायचं
या ट्रायलसाठी भारतामधील 4 हॉस्पिटल्स पेशंट्स घेत आहेत.
रजिस्ट्री सारांश (तांत्रिक)
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
Sponsor: जॅझ फार्मास्युटिकल्स
ClinicalTrials.gov वर NCT06282575
रजिस्ट्रीवर शेवटचे अपडेट 14 Sep 2026 · आम्ही वाचले 20 Oct 2026